Abstract
BackgroundSpecific bio-active dietary compounds modulate numerous metabolic processes in adipose tissue (AT), including pre-adipocyte proliferation and differentiation. AT dysfunction, rather than an increased fat mass per se, is strongly associated with the development of insulin resistance and is characterized by impaired adipogenesis, hypertrophic adipocytes, inflammation, and impairments in substrate metabolism. A better understanding of mechanisms underlying AT dysfunction may provide new strategies for the treatment of obesity-associated metabolic diseases. Here we evaluated the role of (all-E)-lycopene (Lyc), eicosapentaenoic acid (EPA) or trans-resveratrol (Res) and combinations thereof on human white adipocyte function.MethodsIn-vitro differentiating human pre-adipocytes were treated with EPA, Lyc and Res or their combinations for 14 days. The effects on intracellular lipid droplet (LD) accumulation, secreted anti- and pro-inflammatory cyto-/adipokines (e.g. adiponectin, IL-6, IL-8/CXCL-8 and MCP-1/CCL2) and on gene expression of markers of adipocyte differentiation and substrate metabolism (e.g. PPAR-gamma, C/EBP-alpha, GLUT-4, FAS, ATGL, HSL, and PLIN-1) were measured by fluorescent microscopy (Cellomics™), multi-parametric LiquiChip® technology and quantitative RT-PCR, respectively.ResultsTreatment of differentiating adipocytes for 14 days with the combination of Lyc/Res and EPA/Res resulted in significantly inhibited LD formation (~ -25 and -20%, respectively) compared to the effects of the single compounds. These morphological changes were accompanied by increased mRNA levels of the adipogenic marker PPAR-gamma and the lipase ATGL and by decreased expression levels of lipogenic markers (LPL, FAS, GLUT-4) and the LD-covering protein PLIN-1. In addition, a blunted adipocyte secretion of pro-inflammatory cytokines (IL-6 and MCP-1) and adiponectin was observed following treatment with these compounds.ConclusionThe combination of the dietary bio-actives Lyc and EPA with Res might influence adipocyte function by affecting the balance between adipogenic, lipogenic and lipolytic gene expression, resulting in a reduced LD storage and a less inflammatory secretion profile. Taken together, our results indicate that combinations of dietary compounds may be beneficial for the prevention and treatment of metabolic disorders via effects on human white adipocyte function.Electronic supplementary materialThe online version of this article (doi:10.1186/s12986-016-0143-5) contains supplementary material, which is available to authorized users.
Highlights
Specific bio-active dietary compounds modulate numerous metabolic processes in adipose tissue (AT), including pre-adipocyte proliferation and differentiation
Combined treatment with eicosapentaenoic acid (EPA)/ Res at 25/25 μM reduced lipid droplet (LD)-area and -intensity by 22% (p < 0.001) and 26% (p = 0.011), respectively, whereas the LDnumber was slightly attenuated (Fig. 1c). These data indicate that the combination of Lyc/Res and EPA/Res significantly reduced the adipocyte lipid content compared to Diff CTRL
Here we show for the first time, that the combination of the dietary bio-actives Lyc and EPA with Res might influence adipocyte function synergistically by affecting the balance between adipogenic, lipogenic and lipolytic gene expression, resulting in a reduced lipid accumulation and improved inflammatory profile
Summary
Specific bio-active dietary compounds modulate numerous metabolic processes in adipose tissue (AT), including pre-adipocyte proliferation and differentiation. AT dysfunction, characterized by impaired adipogenesis, hypertrophic adipocytes, inflammation, and impairments in lipid and glucose metabolism, rather than an increased body fat mass per se, is strongly associated with the development of insulin resistance [2]. FAs are stored in the form of triacylglycerides (TAGs) in intracellular lipid droplets (LDs) and released by lipolysis, the hydrolysis of TAGs into free FAs and glycerol via the action of intracellular lipases (including hormone sensitive lipase (HSL) and adipose triglyceride lipase (ATGL)) This storage and removal capacity (lipid turn-over) of AT is regulated by a tight alignment between adipogenic differentiation, lipogenesis and lipolysis [3, 4], which has been shown to be impaired in obesity and may modulate whole-body insulin sensitivity [5, 6]. Pro-inflammatory cytokines and chemokines are increasingly secreted by AT cells of obese individuals [10], resulting in a state of ‘lowgrade inflammation’ [11], which affects local adipose metabolism, systemic inflammation and insulin sensitivity
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have